GlassScriptPhysician profile
Shervin Mortazavi
NPI 1740241850
$373,561.90
in general payments reported to CMS, 2019-2025
9 companies · $47K in 2025
The $47K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $8,729 · 2021: $47K · 2022: $69K · 2023: $76K · 2024: $74K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $153K · Consulting Fee: $22K · Travel and Lodging: $16K · Food and Beverage: $6,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $152,730.00 |
| Consulting Fee | $21,593.00 |
| Travel and Lodging | $15,699.09 |
| Food and Beverage | $6,773.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $149,669.91 | 2022-2025 | Ingrezza, Ongentys |
| Astrazeneca Pharmaceuticals LP | $97,043.05 | 2020-2024 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $61,529.75 | 2023-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $61,163.74 | 2019-2021 | |
| Urovant Sciences INC | $3,257.57 | 2021-2022 | |
| Lilly USA, LLC | $502.88 | 2019-2020 | |
| Abbvie INC. | $145.00 | 2019 | |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Acadia Pharmaceuticals INC | $125.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shervin Mortazavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.